The analysis of the level of 5 hmC in the different CpG regions led to the following results: 1) the content of 5 hmC varies among different genes regardless of the TET2 mutational status (Figure 4); 2) changes in the percentage of 5 hmC does not affect different CpGs equally: as shown in Figure 4, CMML patients with TET2-mut showed lower levels of 5 hmC and higher levels of 5 mC in the LAX1 and SLC22A12 CpG's 38 bp upstream and 58 bp downstream, respectively, of the CpG region analyzed in the methylation array but not in the other 2 positions analyzed of the same genes. Here, TET2 is linked to chronic myelomonocytic leukemia.